Board of Directors



Dr. Ascher Shmulewitz, Chairman

Dr. Ascher Shmulewitz has served as our Chairman since January 2014 and on our Board of Directors since February 2013 and was appointed our Interim Chief Executive Officer on November 1, 2017. Dr. Shmulewitz is an inventor, investor and serial entre­pre­neur in biomed­ical technolo­gies. Dr. Shmulewitz has founded and invested in over two dozen life science compa­nies including NeoVision Corp, Labcoat Medical Ltd. Arteria Corp, Circulation Inc. and X‑Cardia Inc., and has led multiple of these compa­nies to successful exits, including through merger and acqui­si­tion trans­ac­tions with large medical device compa­nies. Dr. Shmulewitz has vast experi­ence in the venture capital arena as an investor, manager and entre­pre­neur in dozens of compa­nies and ventures. In 1995, Dr. Shmulewitz co-founded San Francisco Science and the Incumed Group, compa­nies that provide seed funding, and is the founder of Medgenesis Partners Ltd., an Israeli private invest­ment firm and incubator that has invested in over a dozen ventures. Dr. Shmulewitz previ­ously held senior execu­tive positions at Advanced Technology Laboratories Inc. (from 1988 to 1992). Dr. Shmulewitz received an M.D. degree from The Technion Medical School and a Ph.D. degree in Engineering from Tel Aviv University, Israel.


Amit Berger, Independent Director

Mr. Amit Berger has served on our Board of Directors since August 2014. Mr. Berger has signif­i­cant exper­tise in finan­cial markets, where he has held manage­ment and board positions for over twenty-five years. Since 2009, Mr. Berger has served as the Chief Executive Officer of Dolphin 1 Investment Ltd. From 2002 to 2004, Mr. Berger served as the Chairman of Dash Investments Ltd., and from 2005 to 2009, as the Chairman and a director of Enter Holdings 1 Ltd. Mr. Berger has also served on the boards of Mega Or Holdings Ltd., N.R. Spuntech Industries Ltd., Itay Financial A.A. Investments Ltd., Ortam-Sahar Engineering Ltd., Hamashbir 365 Ltd. and Polar Investments Ltd. Mr. Berger holds a B.A. degree in Economics from Tel Aviv University, Israel.


Zohar Heiblum, Independent Director

Mr. Zohar Heiblum has served on our Board of Directors since August 2013. In 1983, Mr. Heiblum co-founded Tefen IL (Israel) Ltd., a leading consulting firm in Israel. Since then, Mr. Heiblum has been involved in various compa­nies as an investor, consul­tant, board member and active Chairman. From 2001, Mr. Heiblum has been an active board member and manager at Momentum Management LLP, which special­izes in manage­ment and invest­ments in turnaround and special situa­tion activ­i­ties, and in his capacity served mostly in High-Tech compa­nies. From 1998 to 2001, Mr. Heiblum served as the a director and Chairman of the board at of Orex Computed Radiography Ltd., which was later sold to Eastern Kodak Company. From 1998 to 2001, Mr. Heiblum served as a director of Biosonix Ltd. which executed a reverse merger with Neoprobe (today Navidea Biopharmaceutical Inc.) in 2002. From 2002 to 2004, Mr. Heiblum served as the general manager of the Israeli subsidiary of MobileAccess Networks Inc. (formally Foxcom) which was sold to Corning Inc. (U.S.A) in 2011. From 2013 to 2014, Mr. Heiblum served as the acting chief execu­tive officer of Alvarion (in receiver­ship) Ltd. and as chairman to Z. Roth Industries Ltd, which is a leading metal designer & producer of products designed to be situated in the public areas, and as of March 2016 acts as the manager of the pre research and devel­op­ment plan on MATIMOP – The Israeli industry center for R&D, which acts as the execu­tive agency of the Israeli Office of the Chief Scientist. Mr. Heiblum has a B.Sc. degree in Industrial Engineering and an M.B.A., both from Tel Aviv University, Israel.


Stephen M. Simes, Director

Mr. Stephen M. Simes has served on our Board of Directors since December 2016. From March 2014 until January 2016, Mr. Simes served as Chief Executive Officer and a member of the Board of Directors of RestorGenex Corporation, a publicly listed company with a focus on oncology (acquired through merger by Diffusion Pharmaceuticals, Inc.). Prior to such time, Mr. Simes served as Vice Chairman, President and Chief Executive Officer and a member of the Board of Directors of BioSante Pharmaceuticals, Inc. from 1998 until June 2013 when BioSante merged with and renamed to ANI Pharmaceuticals, Inc. BioSante, whose common stock was listed on The NASDAQ Global Market, was a specialty pharma­ceu­tical company focused on devel­oping products for women’s and men’s health. From 1994 to 1997, Mr. Simes was President and Chief Executive Officer and a member of the Board of Directors of Unimed Pharmaceuticals, Inc. (currently a wholly owned subsidiary of AbbVie, Inc.), a company with a product focus on infec­tious diseases, AIDS, endocrinology and oncology. From 1989 to 1993, Mr. Simes was Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc., a company which concen­trated on the AIDS, endocrinology, urology and growth disor­ders markets. In 1993, Gynex was acquired by Savient Pharmaceuticals Inc. (formerly Bio-Technology General Corp.), and from 1993 to 1994, Mr. Simes served as Senior Vice President and director of Savient Pharmaceuticals Inc. Mr. Simes’s career in the pharma­ceu­tical industry started with G.D. Searle& Co. (now a part of Pfizer Inc.). Mr. Simes has a B.Sc. degree in Chemistry at Brooklyn College of the City University of New York and an M.B.A. in Marketing and Finance from New York University.


Eric So, Director

Mr. Eric So joined our board in June 2017. Mr. So has over 15 years’ experi­ence advising both private and public compa­nies. He has been the Managing Director, Co-founder and Chief Strategy Officer for Globalive Technology Partners Inc. since December 2017 and has been Chairman of HyperBlock Technologies Corp. since October 2017. Mr. So has served as Chief Legal and Corporate Development Officer, a private internet marketing company, since 2012.  An alumnus of Torys LLP, Eric holds a Bachelor of Science from McGill University and a law degree from the University of Windsor.


Dr. Yafit Stark, Independent Director

Dr. Yafit Stark has served on our Board of Directors since June 2015. Since 2006, Dr. Stark has served as Vice President Global Clinical Advisor at Teva Pharmaceutical Ltd. Dr. Stark has estab­lished the Global Innovative Clinical Research Infrastructures at Teva and was respon­sible for the clinical devel­op­ment of signif­i­cant products, among them the Copaxone® for Multiple Sclerosis. Dr. Stark is a pioneer in incor­po­rating innova­tion and new technolo­gies in clinical devel­op­ment. During her 29 years of work in large pharma, she has built up exper­tise in multiple thera­peutic areas and different types of medic­inal products technolo­gies. Dr. Stark serves as a director of several biotech­nology compa­nies and associ­a­tions. Dr. Stark holds a Ph.D. degree in Pathology from Tel Aviv University and a Post-Doctorate in Immuno-Histopathology from Tel Aviv University and the Weizmann Institute of Science, Israel.